Good Life Advisors LLC Sells 135 Shares of Abbott Laboratories (NYSE:ABT)

Good Life Advisors LLC trimmed its stake in Abbott Laboratories (NYSE:ABT) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,039 shares of the healthcare product maker’s stock after selling 135 shares during the quarter. Good Life Advisors LLC’s holdings in Abbott Laboratories were worth $2,945,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Groupama Asset Managment lifted its position in shares of Abbott Laboratories by 22.2% in the third quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 41,557 shares during the last quarter. Peterson Financial Group Inc. acquired a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $32,000. Valued Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 78.4% in the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 127 shares during the last quarter. Wingate Wealth Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $34,000. Finally, Highline Wealth Partners LLC acquired a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $37,000. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the sale, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Wells Fargo & Company raised their price objective on Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and set a $135.00 price target on shares of Abbott Laboratories in a report on Tuesday, January 21st. StockNews.com cut Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Argus raised Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Stifel Nicolaus lifted their price target on Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $133.06.

Abbott Laboratories Trading Down 0.4 %

Shares of ABT opened at $130.12 on Wednesday. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $132.65. The business’s fifty day moving average is $119.57 and its 200-day moving average is $116.42. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a market cap of $225.68 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 2.39 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11.03 billion. During the same quarter last year, the company posted $1.19 EPS. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 14th. Investors of record on Wednesday, January 15th were given a dividend of $0.59 per share. The ex-dividend date was Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.81%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s payout ratio is currently 30.85%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.